sodium 4-carboxymethoxyimino-(4-HPR)

Sodium 4-carboxymethoxyimino-(4-HPR) is a novel, water-soluble derivative of the synthetic retinoid metabolite 4-oxo-4-HPR, designed to enhance solubility and bioavailability while preserving strong anticancer activity across multiple solid tumor histotypes. Its dual mechanism includes (1) inhibition of microtubule polymerization resulting in mitotic arrest and (2) induction of apoptosis via a reactive oxygen species (ROS)-mediated signaling cascade that leads to endoplasmic reticulum stress and caspase-3 activation. Preclinical models demonstrated significant efficacy in ovarian and breast cancer, mesothelioma, and neuroblastoma, with improved in vivo delivery and potential for low toxicity[1][2].

Other names

3-[8-(4-hydroxyphenylcarbamoyl)-3,7-dimethylocta-1,3,5,7-tetraenyl]-2,4,4-trimethylcyclohex-2-enylideneaminooxy sodium acetatewater-soluble 4-oxo-4-HPR derivativewater-soluble4-oxo-4-HPR derivativewater-soluble-4-oxo-4-HPR derivative